# A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

> **NCT01307267** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 190 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell of Head and Neck
- Malignant Melanoma

## Interventions

- **DRUG:** PF-05082566
- **DRUG:** rituximab
- **DRUG:** PF-05082566

## Key facts

- **NCT ID:** NCT01307267
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06-21
- **Primary completion:** 2019-02-20
- **Final completion:** 2019-02-20
- **Target enrollment:** 190 (ACTUAL)
- **Last updated:** 2020-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01307267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01307267, "A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01307267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*